Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immune-modulating therapies based on proprietary platforms. The company has four phase 3 ready programs in Crohn’s Disease, Fibromyalgia, Multiple Sclerosis and Pancreatic Cancer. The company’s proprietary drug discovery and development program AIMS (Advanced Immunomodulating Multi-receptor System), can generate 100s of analogs for numerous treatments. Through AIMS, Cytocom has expanded its understanding of the relationship between noroxymorphone and proenkephalin analogs determining how multiple factors impact pharmacokinetic – pharmacodynamic relationships, potency, and selectivity. Cytocom has an extensive patent list and a management team with over 17 product approvals and $1 billion in capital raised.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):